BASILEA PHARMACEUTICA
Dead / Abandoned — Abandoned — no statement of use filed (as of 04 Jan 2021)
What this means for you
This application is over — abandoned 04 Jan 2021. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 87222044
- Mark type
- Stylized text
- Filed
- 01 Nov 2016
- Published for opposition
- 03 Oct 2017
- Abandoned
- 04 Jan 2021
- Attorney of record
- Evan A. Raynes
Goods and services
- Class 001 — Chemicals: Chemical substances for use in the manufacture of pharmaceutical preparations for the treatment of dermatological conditions, the treatment of infections and diseases and in the research and development of pharmaceuticals in the treatment of dermatological conditions, the treatment of infections and diseases; diagnostic preparations for scientific clinical use; diagnostic reagents for clinical or medical laboratory use
- Class 005 — Pharmaceuticals: Chemical substances for use in the manufacture of pharmaceutical preparations for the treatment of dermatological conditions, the treatment of infections and diseases and in the research and development of pharmaceuticals in the treatment of dermatological conditions, the treatment of infections and diseases; diagnostic preparations for scientific clinical use; diagnostic reagents for clinical or medical laboratory use (Class 001); Pharmaceutical and veterinary products and preparations for the treatment and prevention of dermatological conditions, namely, eczema, inflammation, infection, warts, psoriasis, aging of the skin, ultra violet radiation and cancer; Veterinary products and preparations for the treatment and prevention of infections caused by bacteria, and Pharmaceutical and veterinary products and preparations for the treatment and prevention of infections caused by fungi, viruses, and rheumatoid arthritis; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of oncology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of gastroenterology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of neurology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of gynecology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of urology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of cardiology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of endocrinology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of nephrology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of hematology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of allergy; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of immunology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of psychiatry; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of anesthesiology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of rheumatology; diagnostic preparations for medical clinical purposes; clinical medical reagents
- Class 042 — Scientific and technological services: Research and development services for third parties in the field of chemical substances, pharmaceutical and veterinary products and preparations
Owner
- Basilea Pharmaceutica International Ltd., Basel, CH
- Basilea Pharmaceutica International Ltd., 4058 Basel, CH
Prosecution history
- 04 Jan 2021 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 04 Jan 2021 — ABANDONMENT - NO USE STATEMENT FILED
- 13 May 2020 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 12 May 2020 — SOU EXTENSION 5 GRANTED
- 30 Apr 2020 — SOU EXTENSION 5 FILED
- 30 Apr 2020 — SOU TEAS EXTENSION RECEIVED
- 26 Oct 2019 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 24 Oct 2019 — SOU EXTENSION 4 GRANTED
- 24 Oct 2019 — SOU EXTENSION 4 FILED
- 24 Oct 2019 — SOU TEAS EXTENSION RECEIVED
- 29 May 2019 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 27 May 2019 — SOU EXTENSION 3 GRANTED
- 27 May 2019 — SOU EXTENSION 3 FILED
- 27 May 2019 — SOU TEAS EXTENSION RECEIVED
- 22 May 2019 — CORRECTED NOA E-MAILED